Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC

Dev Biol Stand. 1994;82:125-9.

Abstract

NYVAC-based recombinants expressing pertinent immunogens from equine influenza virus (EIV), pseudorabies virus (PRV), Japanese encephalitis virus (JEV) and human immunodeficiency virus (HIV) were used to evaluate the safety and immunogenicity of this vector. Administration of either NYVAC recombinants or parenteral virus to mice, horses and swine was well tolerated with no notable local or systemic reactivities. Further, despite a highly attenuated phenotype, NYVAC was found to function effectively as an immunization vehicle capable of eliciting both humoral and cell-mediated immune responses.

Publication types

  • Review

MeSH terms

  • AIDS Vaccines / adverse effects
  • AIDS Vaccines / immunology
  • Animals
  • Antibodies, Viral / biosynthesis
  • Antigens, Viral / genetics
  • Antigens, Viral / immunology
  • Defective Viruses / genetics*
  • Encephalitis Virus, Japanese / genetics
  • Encephalitis Virus, Japanese / immunology*
  • Genetic Engineering
  • Genetic Vectors*
  • HIV / genetics
  • HIV / immunology*
  • HIV Antibodies / biosynthesis
  • HIV Antigens / genetics
  • HIV Antigens / immunology
  • Herpesvirus 1, Suid / genetics
  • Herpesvirus 1, Suid / immunology*
  • Horses
  • Immunity, Cellular
  • Influenza A virus / genetics
  • Influenza A virus / immunology*
  • Mice
  • Pseudorabies Vaccines
  • Safety
  • Swine
  • Vaccination / veterinary
  • Vaccines, Attenuated
  • Vaccines, Synthetic* / adverse effects
  • Vaccines, Synthetic* / immunology
  • Vaccinia virus / genetics*
  • Viral Proteins / genetics
  • Viral Proteins / immunology
  • Viral Vaccines* / adverse effects
  • Viral Vaccines* / immunology

Substances

  • AIDS Vaccines
  • Antibodies, Viral
  • Antigens, Viral
  • HIV Antibodies
  • HIV Antigens
  • NYVAC vaccine
  • Pseudorabies Vaccines
  • Vaccines, Attenuated
  • Vaccines, Synthetic
  • Viral Proteins
  • Viral Vaccines